. 2021 Jun 5;9(6):1228. doi: 10.3390/microorganisms9061228

Table 1.

Descriptive analysis of Brazilian isolates and reference strains included in this study.

Identification				Promastigotes				Amastigotes			MSL
Identification				Miltefosine (mM)		Amphotericin B (nM)		Miltefosine (mM)		Infectivity ^g	MSL
Species ^a	International Code ^b	IOCL# ^c	State ^d	EC₅₀ ± SEM ^e	AI ^f	EC₅₀ ± SEM ^e	AI ^f	EC₅₀ ± SEM ^e	AI ^f	%	Presence/ Absense ^h
L. donovani	LD-15/MHOM/SD/00	NA	NA	9.00 ± 0.82	0.82	35.0 ± 0.5	NA				NA
L. infantum	MHOM/BR/2005/NLC	IOCL3241	MG	10.98 ± 1.95	1.00	51.0 ± 5.0	NA	1.79 ± 0.42	NP	50%	NA
L. infantum	MHOM/BR/2009/BLVD	IOCL 3118	AM	7.07 ± 1.63	0.64	58.0 ± 1.0	1.14				MSL-
L. infantum	MHOM/BR/2006/NMT-HUB402982MO	IOCL 2898	DF	15.61 ± 0.74	1.42	53.0 ± 6.0	1.04				MSL-
L. infantum	MHOM/BR/2005/DRD	IOCL 2788	ES	10.95 ± 1.12	1.0	66.0 ± 4.0	1.29				MSL-
L. infantum	MHOM/BR/2005/HRNS-1	IOCL 2789	ES	8.17 ± 1.04	0.74	62.0 ± 3.0	1.22	4.23 ± 0.53	2.36	66%	MSL-
L. infantum	MCAN/BR/2008/CP-18	IOCL 3068	ES	17.41 ± 1.77	1.59	70.0 ± 0.0	1.37	3.68 ± 0.05	2.06	39%	MSL-
L. infantum	MHOM/BR/2005/804-NMV	IOCL 2943	MA	9.30 ± 0.40	0.85	48.0 ± 7.0	0.94				NA
L. infantum	MHOM/BR/2006/890	IOCL 3694	MA	5.89 ± 0.11	0.54	50.0 ± 2.0	0.98				MSL+
L. infantum	MHOM/BR/2006/6889	IOCL 3696	MA	11.24 ± 1.08	1.02	35.0 ± 4.0	0.69				MSL+
L. infantum	MHOM/BR/2006/6905	IOCL 3699	MA	23.65 ± 1.21	2.15	27.0 ± 6.0	0.53	3.05 ± 0.39	1.70	51%	MSL+
L. infantum	MHOM/BR/2006/MA07A 4P TMS	IOCL 3706	MA	9.85 ± 1.19	0.9	25.0 ± 3.0	0.49				NA
L. infantum	MHOM/BR/2005/841RVSS	IOCL 2977	MA	13.71 ± 1.43	1.25	31.0 ± 0.1	0.61				NA
L. infantum	MHOM/BR/2007/1724FRS	IOCL 2978	MA	16.95 ± 1.14	1.54	34.0 ± 9.0	0.67	3.54 ± 1.03	1.98	64%	NA
L. infantum	MHOM/BR/2007/1728JLM	IOCL 2979	MA	13.29 ± 0.88	1.21	30.0 ± 8.0	0.59				NA
L. infantum	MHOM/BR/2007/1735TAS	IOCL 2981	MA	12.89 ± 1.46	1.17	27.0 ± 5.0	0.53				NA
L. infantum	MHOM/BR/2006/P112A 4P NMV	IOCL 3682	MA	19.68 ± 1.39	1.79	20.0 ± 2.0	0.39				MSL+
L. infantum	MHOM/BR/2006/MA03-A 4P (GMS)	IOCL 3685	MA	23.70 ± 0.78	2.16	30.0 ± 1.0	0.59	3.77 ± 0.01	2.10	50%	MSL+
L. infantum	MHOM/BR/2002/LPC-RPV	IOCL 2906	MG	8.15 ± 1.29	0.74	43.0 ± 16.0	0.84				MSL-
L. infantum	MHOM/BR/2011/AD1	IOCL 3368	MG	11.07 ± 1.50	1.01	28.0 ± 2.0	0.55				MSL-
L. infantum	MHOM/BR/2011/CR1	IOCL 3370	MG	7.30 ± 1.40	0.66	63.0 ± 1.0	1.24				MSL-
L. infantum	MHOM/BR/2012/AD5	IOCL 3383	MG	14.29 ± 0.91	1.3	53.0 ± 5.0	1.04				NA
L. infantum	MHOM/BR/2012/AD7	IOCL 3385	MG	7.51 ± 0.91	0.68	39.0 ± 14.0	0.76				NA
L. infantum	MHOM/BR/2012/CR2	IOCL 3386	MG	9.45 ± 0.97	0.86	64.0 ± 8.0	1.25				NA
L. infantum	MCAN/BR/2010/CA1	IOCL 3378	MG	20.72 ± 1.90	1.89	41.0 ± 11.0	0.8				MSL-
L. infantum	MCAN/BR/2010/CA2	IOCL 3379	MG	12.64 ± 1.30	1.15	30.0 ± 2.0	0.59	4.57 ± 1.09	2.55	52%	MSL-
L. infantum	MCAN/BR/2002/LVV-137	IOCL 2666	MS	9.82 ± 0.34	0.89	51.0 ± 3.0	1.00				MSL+
L. infantum	MCAN/BR/2010/MEG	IOCL 3214	MS	7.10 ± 0.54	0.65	62.0 ± 7.0	1.22				MSL-
L. infantum	MCAN/BR/2002/LVV-136	IOCL 2665	MS	16.26 ± 1.36	1.48	26.0 ± 3.0	0.51				MSL+
L. infantum	MHOM/BR/2009/202	IOCL 3140	MT	7.73 ± 1.32	0.7	51.0 ± 13.0	1.00				NA
L. infantum	MCAN/BR/2009/GRANDÃO I	IOCL 3134	MT	9.31 ± 0.09	0.85	56.0 ± 8.0	1.10				NA
L. infantum	MCAN/BR/2009/GRANDÃO II	IOCL 3135	MT	11.46 ± 0.98	1.04	46.0 ± 4.0	0.90				NA
L. infantum	MCAN/BR/2009/SOL	IOCL 3137	MT	9.79 ± 0.43	0.89	47.0 ± 3.0	0.92				NA
L. infantum	MHOM/BR/2006/791	IOCL 3698	PA	12.37 ± 1.70	1.13	35.0 ± 6.0	0.69				MSL-
L. infantum	MHOM/BR/2008/RJS	IOCL 3053	PE	14.35 ± 0.39	1.31	60.0 ± 6.0	1.18				MSL-
L. infantum	MHOM/BR/2005/742EMS	IOCL 2972	PI	23.45 ± 1.06	2.14	41.0 ± 5.0	0.80				MSL+
L. infantum	MHOM/BR/2006/1406MBS	IOCL 2976	PI	7.73 ± 1.16	0.7	49.0 ± 1.0	0.96	3.27 ± 0.01	1.83	46%	MSL-
L. infantum	MHOM/BR/2005/867-JNS	IOCL 2944	PI	7.59 ± 0.84	0.69	53.0 ± 6.0	1.04				NA
L. infantum	MHOM/BR/2005/792FFS	IOCL 2973	PI	14.47 ± 1.36	1.32	68.0 ± 11.0	1.33				NA
L. infantum	MHOM/BR/2006/891	IOCL 3692	PI	6.73 ± 1.42	0.61	36.0 ± 5.0	0.71				MSL+
L. infantum	MHOM/BR/2006/930	IOCL 3693	PI	12.03 ± 1.08	1.1	62.0 ± 21.0	1.22				MSL+
L. infantum	MHOM/BR/2006/P109A 4P JAS	IOCL 3688	PI	8.03 ± 0.42	0.73	35.0 ± 6.0	0.69				MSL+
L. infantum	MHOM/BR/2006/867	IOCL 3695	PI	8.45 ± 0.84	0.77	34.0 ± 8.0	0.67				MSL-
L. infantum	MHOM/BR/2006/6893	IOCL 3697	PI	8.41 ± 1.21	0.77	37.0 ± 7.0	0.73	3.41 ± 0.75	1.91	69%	MSL+
L. infantum	MHOM/BR/2006/6914	IOCL 3700	PI	9.76 ± 1.58	0.89	38.0 ± 3.0	0.75				MSL+
L. infantum	MHOM/BR/2006/AAS 3P	IOCL 3703	PI	22.06 ± 1.58	2.01	32.0 ± 8.0	0.63	4.04 ± 0.76	2.26	79%	MSL-
L. infantum	MHOM/BR/2006/AAS 4P	IOCL 3704	PI	9.49 ± 1.88	0.86	33.0 ± 9.0	0.65				MSL+
L. infantum	MHOM/BR/2006/Pi 11A 4P MBS	IOCL 3705	PI	10.51 ± 0.52	0.96	34.0 ± 12.0	0.67				MSL-
L. infantum	MHOM/BR/2007/1732EPG	IOCL 2980	PI	15.22 ± 0.68	1.39	32.0 ± 3.0	0.63				NA
L. infantum	MHOM/BR/2007/1739MSS	IOCL 2982	PI	13.37 ± 1.70	1.22	27.0 ± 0.0	0.53				NA
L. infantum	MHOM/BR/2006/6909	IOCL 3680	PI	15.41 ± 0.80	1.4	29.0 ± 0.5	0.57	1.69 ± 0.56	0.94	36%	MSL+
L. infantum	MHOM/BR/2006/6912	IOCL 3681	PI	13.34 ± 1.13	1.21	26.0 ± 4.0	0.51				MSL+
L. infantum	MHOM/BR/2006/JSMG 3P	IOCL 3683	PI	11.26 ± 2.07	1.03	30.0 ± 1.0	0.59				MSL+
L. infantum	MHOM/BR/2006/ARS 3P	IOCL 3684	PI	12.20 ± 1.37	1.11	27.0 ± 5.0	0.53				MSL-
L. infantum	MHOM/BR/2006/FFS 3P PI-05	IOCL 3687	PI	20.45 ± 1.09	1.86	23.0 ± 1.0	0.45	3.09 ± 0.97	1.73	61%	MSL+
L. infantum	MHOM/BR/2006/RUSS-3P	IOCL 3701	PI*	16.04 ± 2.02	1.46	31.0 ± 4.0	0.61				NA
L. infantum	MHOM/BR/2006/Pi 04A 4P DHRi	IOCL 3702	PI*	8.25 ± 1.38	0.75	27.0 ± 5.0	0.53				MSL+
L. infantum	MHOM/BR/2006/MA01-A 4P	IOCL 3707	PI*	9.46 ± 1.40	0.86	32.0 ± 6.0	0.63				MSL+
L. infantum	MHOM/BR/2006/MA04A 4P JNN	IOCL 3686	PI*	16.20 ± 0.78	1.48	31.0 ± 2.0	0.61				MSL-
L. infantum	MCAN/BR/2015/TUBO9	IOCL 3598	RJ	11.63 ± 0.48	1.06	34.0 ± 3.0	0.67				MSL-
L. infantum	MHOM/BR/2011/Diag 1367	IOCL 3330	RN	8.24 ± 1.13	0.75	36.0 ± 2.0	0.71				MSL-
L. infantum	MHOM/BR/2011/TC 03	IOCL 3336	RN	6.56 ± 0.66	0.6	29.0 ± 0.0	0.57				MSL-
L. infantum	MHOM/BR/2011/TC 18	IOCL 3339	RN	6.37 ±0.29	0.58	38.0 ± 2.0	0.75	1.41 ± 0.50	0.79	70%	MSL-
L. infantum	MHOM/BR/2011/TC 28	IOCL 3340	RN	8.07 ± 1.24	0.73	56.0 ± 16.0	1.10				MSL-
L. infantum	MHOM/BR/2011/TC 50	IOCL 3341	RN	9.06 ±0.60	0.83	55.0 ± 4.0	1.08				MSL-
L. infantum	MHOM/BR/2011/TC 65	IOCL 3342	RN	9.75 ± 0.60	0.89	41.0 ± 1.0	0.8				MSL-
L. infantum	MHOM/BR/2011/TC 95	IOCL 3343	RN	9.86 ± 0.50	0.9	45.0 ± 6.0	0.88				MSL-
L. infantum	MHOM/BR/2011/TC 96	IOCL 3344	RN	7.45 ± 0.62	0.68	56.0 ± 9.0	1.10				NA
L. infantum	MHOM/BR/2011/TC 98	IOCL 3345	RN	8.53 ± 0.81	0.78	66.0 ± 6.0	1.29				NA
L. infantum	MHOM/BR/2011/TC 105	IOCL 3346	RN	9.91 ± 0.76	0.9	43.0 ± 15.0	0.84				NA
L. infantum	MHOM/BR/2011/TC 115	IOCL 3347	RN	7.35 ± 0.69	0.67	40.0 ± 3.0	0.78				NA
L. infantum	MHOM/BR/2011/TC 86	IOCL 3388	RN	8.69 ± 0.21	0.79	69.0 ± 9.0	1.35				NA
L. infantum	MCAN/BR/2010/LUNA II	IOCL 3196	RS	10.88 ± 0.88	0.99	48.0 ± 2.0	0.94				MSL-
L. infantum	MCAN/BR/2011/IMTS-14	IOCL 3257	SP	20.11 ± 1.52	1.83	40.0 ± 5.0	0.78				MSL-
L. infantum	MCAN/BR/2008/Lchagasi-UFRJ	IOCL 3324	SP	20.79 ± 0.82	1.89	46.0 ± 4.0	0.90	2.04 ± 0.46	1.14	89%	NA

^a Two Leishmania species, L. donovani and L. infantum were used in this study. ^b International Code for each isolate/strain used in this work. MHOM are isolates obtained from humans, MCAN are isolates from dogs. The strains from patients who participated in the Miltefosine clinical trial (IOCL 2943, IOCL 2944, IOCL 2973, IOCL 3692, IOCL 3693, IOCL 3694) are identified in bold. ^c Codes for Leishmania strains deposited in the Leishmania Collection at Fundação Oswaldo Cruz (CLIOC). ^d Brazilian State of origin of the isolates. AM = Amazonas; DF = Distrito Federal; ES = Espírito Santo; MA = Maranhão; MG = Minas Gerais; MS = Mato Grosso do Sul; MT = Mato Grosso; PA = Pará; PE = Pernambuco; PI = Piauí; RJ = Rio de Janeiro; RN = Rio Grande do Norte; RS = Rio Grande do Sul; SP = São Paulo. PI* Brazilian State of the institution that sent the isolates (State of origin of sample not confirmed). ^e EC₅₀ ± SEM of miltefosine determined for promastigotes (in three independent experiments) and amastigotes (in two independent experiments) and of amphotericin B for promastigotes (also in two independent experiments). ^f Activity index was calculated by dividing the EC₅₀ of each clinical isolate by the EC₅₀ of the L. infantum reference strain NLC. NP = not applicable. ^g Mean percentage of infection obtained for each isolate/strain after 72 h of infection and in the absence of drug. ^h MSL = miltefosine sensitivity locus. MSL+ indicates the presence of the locus in homozygosis; MSL- absence of the referred locus in homozygosis; NA = not available. Data reported in Schwabl, et al. [24].